HALOZYME THERAPEUTICS, INC.
Last 30 daysNo qualifying insider buying. Sales: $9.05M by 2 insiders.
Showing the first 6 of 20 trades on this page.
Director
Restricted Stock Units
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Restricted Stock Units
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP, PRESIDENT, DRUG DELIVERY
Common Stock
The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.
EVP, PRESIDENT, DRUG DELIVERY
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Restricted Stock UnitsGrant or award | Derivative units1,169Award · no purchase price | Non-cash award | Oct 1Filed Oct 2 · 1d later | SEC filing |
| Director | Option to Purchase Common StockGrant or award | Derivative units1,775Award · no purchase price | Non-cash award | Oct 1Filed Oct 2 · 1d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 9Filed Sep 11 · 2d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 10Filed Sep 11 · 1d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 11Filed Sep 11 · 0d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Sep 9Filed Sep 11 · 2d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Sep 10Filed Sep 11 · 1d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Sep 11Filed Sep 11 · 0d later | SEC filing |
| Director | Restricted Stock UnitsGrant or award | Derivative units1,161Award · no purchase price | Non-cash award | Sep 1Filed Sep 2 · 1d later | SEC filing |
| Director | Option to Purchase Common StockGrant or award | Derivative units1,778Award · no purchase price | Non-cash award | Sep 1Filed Sep 2 · 1d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Aug 17Filed Aug 19 · 2d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Aug 18Filed Aug 19 · 1d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Aug 19Filed Aug 19 · 0d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Aug 17Filed Aug 19 · 2d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Aug 18Filed Aug 19 · 1d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units20,000$18.41 exercise / conversion price | Not a separate purchase | Aug 19Filed Aug 19 · 0d later | SEC filing |
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 1,923$12.07 / share | $23.21K | Jul 8Filed Jul 9 · 1d later | SEC filing |
| PRESIDENT AND CEO | Option to Purchase Common StockOption exercise or conversion10b5-1 | Derivative units1,923$12.07 exercise / conversion price | Not a separate purchase | Jul 8Filed Jul 9 · 1d later | SEC filing |
| EVP, PRESIDENT, DRUG DELIVERY | Common StockOption exercise or conversion | 10,000$0 reported · see filing | Not established | Jun 30Filed Jul 2 · 2d later | SEC filing |
| EVP, PRESIDENT, DRUG DELIVERY | Common StockExercise-price or tax withholding | 5,408$78.27 / share | $423.28K | Jun 30Filed Jul 2 · 2d later | SEC filing |
Showing the latest 20 of 61 trades. Show all 61 trades
Halozyme Therapeutics, Inc. - Common Stock (HALO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
